Dr. Thomas G. Chu, MD

Dr. Chu practices at Retina-Vitreous Associates Medical Group in Los Angeles, California.

Dr. Chu's NPI, 1760482806, was assigned on July 29, 2005. Dr. Chu graduated from Icahn School Of Medicine At Mount Sinai in 1986. Dr. Chu's California license number on file is G68694.

Dr. Chu's primary practice is Retina-Vitreous Associates Medical Group, at 1245 W Wilshire Blvd, Los Angeles, CA 90017 in Los Angeles County. The practice phone is (213) 483-8810.

Dr. Chu's primary practice is Retina-Vitreous Associates Medical Group in Los Angeles, California. Dr. Chu is also affiliated with PIH Health Good Samaritan Hospital. Dmand AI also links Dr. Chu to 1 more medical group, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Chu practices. Vendor and product names are available with a free account.

Ophthalmology is Dr. Chu's primary specialty in the NPI Registry, under taxonomy code 207W00000X. Dr. Chu is board certified in ophthalmology by the American Board of Ophthalmology. Dmand AI has Dr. Chu's licenses on file in 3 states: California, Nevada and Utah.

Dmand AI lists age-related macular degeneration, cataract, conjunctivitis, dry eye, eye infection or inflammation, eyelid inflammation, glaucoma and hereditary corneal conditions among the conditions Dr. Chu treats.

CMS data shows 26,513 Medicare services from Dr. Chu across 16 procedure codes in 2024, for 1,203 Medicare patients. Medicare paid $1,920,345 for them. Every service was in an office.

CMS counts 1,203 Medicare patients who saw Dr. Chu in 2024. The largest group is 65 to 74, with 456 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 36% are also on Medicaid. Their average risk score is 1.61, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Chu's median patient age at 65, with 48% women.

In 2024, Dr. Chu wrote 1,149 Medicare Part D claims for 332 patients. 74% of them were for generic drugs. CMS names the drug for 1,047 of them, across 17 drugs with 11 or more claims each, at $130,510 in total drug cost. In 2023, CMS named 1,179 claims across 19 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Chu for performance year 2024, reported as part of a group. Dr. Chu accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links Dr. Chu to 2 clinical trials. Conditions studied include Macular Degeneration and Retinal Degeneration.

CMS Open Payments shows 105 general payments to Dr. Chu from 13 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 70% of the total. Genentech, Inc. paid the most, $1,256.

Dmand AI lists 3 awards for Dr. Chu, most recently CMS Stage 1 EHR in 2013.

Dr. Chu graduated from Icahn School Of Medicine At Mount Sinai in 1986. Dr. Chu is a member of AAO.

Dr. Chu is in network with 12 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 11. Check the plan with the practice before a visit.